- Home
- VSTM vs CMRX Comparison
VSTM vs CMRX Comparison
Compare VSTM & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- CMRX
- Stock Information
- Founded
- VSTM 2010
- CMRX 2000
- Country
- VSTM United States
- CMRX United States
- Employees
- VSTM N/A
- CMRX N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- CMRX Health Care
- Exchange
- VSTM Nasdaq
- CMRX Nasdaq
- Market Cap
- VSTM 132.0M
- CMRX 77.0M
- IPO Year
- VSTM 2012
- CMRX 2013
- Fundamental
- Price
- VSTM $3.88
- CMRX $0.93
- Analyst Decision
- VSTM Strong Buy
- CMRX Strong Buy
- Analyst Count
- VSTM 8
- CMRX 1
- Target Price
- VSTM $14.57
- CMRX $11.00
- AVG Volume (30 Days)
- VSTM 1.1M
- CMRX 119.4K
- Earning Date
- VSTM 11-06-2024
- CMRX 11-08-2024
- Dividend Yield
- VSTM N/A
- CMRX N/A
- EPS Growth
- VSTM N/A
- CMRX N/A
- EPS
- VSTM N/A
- CMRX N/A
- Revenue
- VSTM $10,000,000.00
- CMRX $144,000.00
- Revenue This Year
- VSTM N/A
- CMRX $3,040.12
- Revenue Next Year
- VSTM $125.69
- CMRX N/A
- P/E Ratio
- VSTM N/A
- CMRX N/A
- Revenue Growth
- VSTM N/A
- CMRX N/A
- 52 Week Low
- VSTM $2.10
- CMRX $0.75
- 52 Week High
- VSTM $14.22
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- VSTM 63.77
- CMRX 60.78
- Support Level
- VSTM $3.11
- CMRX $0.80
- Resistance Level
- VSTM $3.76
- CMRX $0.98
- Average True Range (ATR)
- VSTM 0.33
- CMRX 0.05
- MACD
- VSTM 0.04
- CMRX 0.01
- Stochastic Oscillator
- VSTM 94.26
- CMRX 83.33
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.